Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET

Company Participants

Susie Lisa - Senior Vice President, Investor Relations
Dr. Reshma Kewalramani - President and CEO
Stuart Arbuckle - Chief Operating Officer
Charlie Wagner - Chief Financial Officer

Conference Call Participants

Jessica Fye - J.P. Morgan
Salveen Richter - Goldman Sachs
Chris Garcia - Morgan Stanley
Mohit Bansal - Wells Fargo
Tazeen Ahmad - Bank of America
Michael Yee - Jefferies
Evan Seigerman - BMO Capital Markets
Phil Nadeau - TD Cowen
Debjit Chattopadhyay - Guggenheim Partners
Olivia Brayer - Cantor Fitzgerald
Liisa Bayko - Evercore ISI

Operator

Good day. And welcome to the Vertex Pharmaceuticals Third Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note this event is being recorded.

I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead, ma’am.

Susie Lisa

Good evening, everyone. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our third quarter 2024 financial results conference call. On tonight’s call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex’s CEO and President; Stuart Arbuckle, Chief Operating Officer; and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded and a replay will be available on our website.

We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today’s press release and in our filings with the Securities and Exchange Commission.

These statements, including without limitation, those regarding Vertex’s marketed medicines for cystic fibrosis, sickle cell disease and beta thalassemia, our pipeline, including the potential near-term launches of the vanzacaftor triple in CF and suzetrigine in moderate to severe acute pain, and Vertex’s future financial performance, are based on management’s current assumptions. Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis.

I will now turn the call over to Reshma.

Dr. Reshma Kewalramani

Thanks, Susie. Good evening, all, and thank you for joining us on the call today. Third quarter performance extended our strong momentum for the year, with continued outstanding commercial execution in both CF and the early launch of CASGEVY, as well as launch preparedness for two potential near-term approvals in early 2025. We also continued to rapidly progress programs in our clinical pipeline and achieved a significant milestone with three new programs advancing into Phase 3 clinical trials in just the last quarter.